September Research Rounds
PRiME Research Rounds is a monthly research presentation featuring talks from PRiME Principal Investigators and Fellows. The seminar sessions bring the PRiME community together for engaging discussions!
Date: Friday, September 25, 2026, 1:00 - 2:00PM (Light refreshments will be provided)
Location: Red Seminar Room, Terrence Donnelly Centre, 160 College Street
Speakers:
Dr. Stephane Angers
PRiME PI
Professor & Director, Donnelly Centre for Cellular + Biomolecular Research
Charles H. Best Chair of Medical Research
“Development of Remigromig to treat eye diseases”
Dr. Stephane Angers is an internationally recognized expert in signal transduction. He earned his Ph.D. from the Université de Montréal in 2002 under the supervision of Dr. Michel Bouvier, where his doctoral research led to the development and application of light energy transfer methodologies to study protein–protein interactions and cellular signalling. From 2002 to 2006, he was a Howard Hughes Medical Institute Postdoctoral Fellow at the University of Washington in Seattle in the laboratory of Dr. Randall T. Moon. During this period, he identified and characterized novel components of the Wnt signalling pathway and discovered a new class of E3 ubiquitin ligases.
In October 2006, Dr. Angers established his independent research program at the University of Toronto, with appointments in the Department of Pharmaceutical Sciences, Faculty of Pharmacy, and the Department of Biochemistry. He currently holds the Canada Research Chair in Functional Architecture of Signal Transduction. His research focuses on understanding Wnt growth factor signalling in development, adult tissue homeostasis, and human disease. His pioneering work has enabled the development of novel antibody-based therapeutics that block or activate Wnt signalling for applications in cancer and regenerative medicine.
Dr. Angers is the scientific co-founder of AntlerA Therapeutics, which was acquired by Roche in 2024. His work led to the development of Restoret (MK-3000), a trispecific tetravalent FZD4:LRP5 agonist currently in Phase 2b/3 clinical trials for diabetic macular edema. In September 2021, Dr. Angers was appointed Director of the Donnelly Centre for Cellular and Biomolecular Research at the University of Toronto.
Nitzan Letko Khait
Research Associate
Department of Chemical Engineering & Applied Chemistry, University of Toronto
“Sustained Chondroitinase ABC-37 Delivery Enhances Cell Survival and Recovery After Stroke”
Nitzan Letko Khait is a Research Associate in Prof. Molly Shoichet's lab at the University of Toronto. Her research focuses on the development of a biomaterial-enzyme based strategy to promote neural repair following stroke. Her work integrates tissue engineering, preclinical validation, and entrepreneurship to advance this technology from academic research toward clinical translation.